✕
Login
Register
Back to News
UBS Maintains Buy on Celldex Therapeutics, Raises Price Target to $45
Benzinga Newsdesk
www.benzinga.com
Positive 84.3%
Neg 0%
Neu 0%
Pos 84.3%
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment